Panagora Asset Management Inc. Boosts Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Panagora Asset Management Inc. lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 90.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 174,144 shares of the company's stock after purchasing an additional 82,645 shares during the period. Panagora Asset Management Inc. owned about 0.21% of Syndax Pharmaceuticals worth $3,763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. CWM LLC boosted its position in Syndax Pharmaceuticals by 415.3% during the fourth quarter. CWM LLC now owns 1,685 shares of the company's stock worth $36,000 after purchasing an additional 1,358 shares in the last quarter. MeadowBrook Investment Advisors LLC purchased a new stake in Syndax Pharmaceuticals in the 4th quarter worth $37,000. Quadrant Capital Group LLC raised its position in Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company's stock worth $53,000 after acquiring an additional 1,496 shares during the period. Annandale Capital LLC purchased a new position in Syndax Pharmaceuticals during the third quarter valued at $67,000. Finally, Signaturefd LLC grew its position in shares of Syndax Pharmaceuticals by 2,874.6% in the fourth quarter. Signaturefd LLC now owns 3,748 shares of the company's stock valued at $81,000 after purchasing an additional 3,622 shares during the period.

Syndax Pharmaceuticals Trading Down 3.0 %

SNDX traded down $0.63 during mid-day trading on Friday, hitting $20.29. 957,497 shares of the stock were exchanged, compared to its average volume of 893,226. The firm's fifty day moving average is $22.16 and its two-hundred day moving average is $20.64. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34. The company has a market cap of $1.72 billion, a PE ratio of -6.30 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same quarter last year, the firm posted ($0.59) EPS. As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SNDX. JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Scotiabank lowered shares of Syndax Pharmaceuticals from a "sector outperform" rating to a "sector perform" rating and dropped their target price for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. Stifel Nicolaus raised their price target on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 9th. HC Wainwright reissued a "buy" rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Thursday, May 9th. Finally, Citigroup dropped their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.42.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).